Velmetia

(sitagliptin;metformin)

Uses, side effects, dosage information & price range

Merck Sharp & Dohme B.V.

About this medicine

For patients with type-2 diabetes mellitus: Velmetia is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. Velmetia is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea. Velmetia is indicated as triple combination therapy with a PPAR agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist. Velmetia is also indicated as add on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.

Common Substitutes & Alternatives

These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.

EfficibComposition: sitagliptin;metforminMerck Sharp and Dohme B.V

Price on RequestView Details →

JanumetComposition: sitagliptin;metforminMerck Sharp & Dohme B.V.

Price on RequestView Details →

Key Information

Salt / Composition

sitagliptin;metformin